Pecuniary and non-pecuniary incentives in prescription pharmaceuticals: The case of statins

B.E. Journal of Economic Analysis and Policy

Volumn 11, Issue 2, 2011, Pages

  Limbrock, Frank ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

demand; HMO; managed care; pharmaceuticals; prescription drugs; statins

Indexed keywords

EID: 79951530353     PISSN: None     EISSN: 19351682     Source Type: Journal    
DOI: 10.2202/1935-1682.2665     Document Type: Article

References (17)

1. American Heart Association (2006): "Heart disease and stroke statistics: 2006 update," Retrieved August 2009, from the American Heart Association: http://www.americanheart.o.rg
2. Berndt, E. (2002): "Pharmaceuticals in u.s. health care: Determinants of quantity and price," Journal of Economic Perspectives, 16, 45-66.
3. Chicago Tribune (2008): "CVS Caremark settles deceptive-practices complaint for $38.5 million," February 14.
4. Duggan, M. and F. Scott Morton (2010): "The effect of medicare part d on pharmaceutical prices and utilization, " American Economic Review, 100, 590-607.
5. Esposito, D. (2005): "Prescription drug demand for therapeutic substitutes: The influence of copayments and insurer non-price rationing," Journal of Pharmaceutical Finance, Economics & Policy, 14, 590-607.
6. Gaynor M., J. L. and W. Vogt (2007): "Substitution, spending offsets, and prescription drug benefit design, " Forum for Health Economics & Policy, 10, Article 4.
7. Goldman, D., G. Joyce, J. Escarce, J. Pace, M. Solomon, M. Laouri, P. Landsman, and S. Teutsch (2004): "Pharmacy benefits and the use of drugs by the chronicall (Pubitemid 38656301)
8. Goldman, D., G. Joyce, and P. Karaca-Mandic (2006): "Varying pharmacy benefits with clinical status: The case of cholesterol-lowering therapy, " The American Journal of Managed Care, 12, 21-28. (Pubitemid 43139537)
9. Hellerstein, J. (1998): "The importance of the physician in the generic versus tradename prescription decision, " Rand Journal of Economics, 29, 108-136. (Pubitemid 128351561)
10. Ho, K. (2009): "Insurer-provider networks in the medical care market, " American Economic Review, 99, 393-430.
11. Huskamp, H., P. Deverka, A. Epstein, R. Epstein, K. McGuigan, and R. Frank (2003): "The effect of incentive-based formularies on prescription drug utilization and spending," New England Journal of Medicine, 349, 2224-2232. (Pubitemid 37485139)
12. IMS Health (2005): "IMS national sales perspectives, 2=2005,"
13. IMS Health (2008): "U.S. pharmaceutical market performance review, 2007" .
14. Joyce, G., J. Escarce, M. Solomon, and D. Goldman (2002): "Employer drug benefit plans and spending on prescription drugs, " Journal of the American Medical Association, 288, 1733-1739.
15. Ma, C. and T. McGuire (2002): "Network incentives in managed health care, " Journal of Economics and Management Strategy, 11, 1-35.
16. Schultz, J., J. O'Donnell, K. McDonough, R. Sasane, and J. Meyer (2005): "Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population, " American Journal of Managed Care, 11, 306-312. (Pubitemid 40646935)
17. Thomson Medstat (2001): "Market Scan Database, " Ann Arbor, MI.